Application of Human Three-Dimensional Multicellular Models for Personalized Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 July 2024 | Viewed by 1757

Special Issue Editor


E-Mail
Guest Editor
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, H02-312, Marchioninistrasse 15, 81377 Munich, Germany
Interests: personalized cancer therapy; functional diagnostics; cancer modeling; patient-derived cancer spheroids; innovative treatment options

Special Issue Information

Dear Colleagues,

Personalized cancer therapy based on individual tumor characteristics is playing an increasingly important role in cancer treatment. Currently, personalized oncology is mainly defined as the molecular profiling of tumors to select a targeted therapy for the individual cancer patient. However, a significant number of cancer patients do not benefit from this treatment selection strategy. This highlights the need to consider additional tumor characteristics relevant to drug response and to incorporate additional testing systems beyond the evaluation of genetic information into the treatment decision process.

The Special Issue "Application of Three-Dimensional Human Multicellular Models for Personalized Cancer Therapy" aims to provide an update on complex 3D human cancer models such as organoids, spheroids, tissue cultures, on-a-chip platforms, bioprinted models, and microfluidic systems developed for drug selection for individual cancer patients.

Dr. Barbara Mayer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • complex human 3D cancer models
  • patient-derived 3D cancer models
  • functional diagnostics
  • personalized therapy
  • efficacy testing
  • toxicity testing
  • automated drug selection
  • combined drug selection strategies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3892 KiB  
Article
An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids
by Amanda Mueggler, Eléa Pilotto, Nadja Perriraz-Mayer, Sicong Jiang, Alfredo Addeo, Benoît Bédat, Wolfram Karenovics, Frédéric Triponez and Véronique Serre-Beinier
Cancers 2023, 15(23), 5576; https://doi.org/10.3390/cancers15235576 - 25 Nov 2023
Viewed by 1422
Abstract
Lung cancer is the leading cause of cancer mortality worldwide, with a median survival rate at 5 years of less than 20%. While molecular mapping aids in selecting appropriate therapies, it cannot predict personalized treatment response and long-term efficacy. For addressing these challenges, [...] Read more.
Lung cancer is the leading cause of cancer mortality worldwide, with a median survival rate at 5 years of less than 20%. While molecular mapping aids in selecting appropriate therapies, it cannot predict personalized treatment response and long-term efficacy. For addressing these challenges, there is a great need for functional tests. Within this context, we developed patient-derived spheroids (PDS) from tumor and adjacent normal tissue to biomimic the respective tissue for assessing the personalized drug treatment response in vitro. Surgically resected lung specimens were used to generate spheroids using a two-step culture procedure. Flow cytometry and immune staining enabled the characterization of different cell populations resulting from the lung samples. PDS phenotype, cell proliferation and apoptosis were evaluated. Differential gene expression between tumor and adjacent normal tissue was analyzed via RT-qPCR. PDS drug sensitivity was assessed using a cell metabolic assay in response to two chemotherapeutic drug combinations. Cellular and molecular analysis revealed the proportion of epithelial cells, fibroblasts, and immune cells in the patients’ tissue samples. Subsequently, PDS models from tumor and normal lung were successfully established using the expanded epithelial cells. As a proof of concept, an analysis of the drug treatment using PDS of lung adenoid cystic carcinoma exhibited a dose-dependent effect in response to cisplatin/etoposide and cisplatin/paclitaxel. Our spheroid model of both tumor and non-tumor lung cells holds great promise for enhancing the treatment efficacy in the cancer patients. Full article
Show Figures

Figure 1

Back to TopTop